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Krumm et al., page 595; Poultney et al., page 607
The role of copy-number variation in complex disease
has received substantial interest lately. Many of these
recent studies have relied on microarray analysis for
calling copy-number variants (CNVs). However, the
lower size limit for detection by microarray renders it
ineffective for calling CNVs of less than 30 kb, leaving
questions about the contribution of these small CNVs
to various genetic diseases. Two recently introduced
methods of calling CNVs from exome sequencing data
circumvent the limits of microarray: CoNIFER and
XHMM. In this issue, studies by Krumm et al. and
Poultney et al. use CoNIFER and XHMM, respectively,
to identify small CNVs associated with autism spectrum
disorder (ASD) and validate the accuracy by using trans-
mission information from families with one and two
children (trios and quads, respectively). Both studies
determined that individuals with ASD had a higher
burden of small CNVs (median size 18 kb) than did indi-
viduals without ASD. Unlike previously identified large
CNVs, small CNVs might only affect a single gene,
providing the prospect of refining which individual pro-
tein-coding genes, when disrupted, might cause autism.
To this end, Krumm et al. found an enrichment of
brain-expressed genes and Poultney et al. identified an
enrichment of genes involved in the cytoskeleton and
autophagy pathways. Not only do these studies highlight
new areas for ASD research to explore, but they also
emphasize the utility of CoNIFER and XHMM for identi-
fying a range of CNVs from exome sequencing data
across a variety of complex diseases.Targeted Therapies for a Rare Genetic Disorder
Aufenvenne et al., page 620
Efforts in personalized medicine are largely aimed
at treating diseases with relatively high frequencies;
however, the number of rare diseases that are being gene-
tically solved also provides the opportunity to develop
targeted therapies. Skin conditions appear to be an
ideal niche for the application of personalized medicine
because skin is accessible for topical treatment. In this
study, Aufenvenne et al. demonstrate the effectiveness of
a topical therapy for autosomal-recessive congenital1Scientific Editor, AJHG; 2Deputy Editor, AJHG
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The Americicthyosis (ARCI) caused by a deficiency in transgluta-
minase 1 (TG1), an enzyme important for crosslinking
structural proteins for the establishment of the skin
barrier against water loss and infection. Individuals born
with ARCI are encased in collodion membranes and
later develop scales accompanied by severe water loss
through the skin. Typically, treatment is meant to provide
symptom relief rather than correct TG1 deficiency. Via
improved delivery through lipopeptide-modified lipo-
somes, TG1 was integrated into keratinocytes derived
from individuals with ARCI. Moreover, treatment of mice
with human TG1-deficient skin grafts improved the
phenotypic hallmarks of ARCI, including reduction of
cholesterol clefts and transepidermal water loss. Although
many efforts in personalized medicine are aimed at
diseases with higher frequencies than that of ARCI,
targeted therapies for very rare diseases should not be
overlooked.Lurking inside Your Genome
Dorschner et al., page 631
With the integration of next-generation sequencing into
clinical practices, physicians are struggling with how to
both interpret and report on the massive amounts of
data that are being collected. A key question is which
so-called ‘‘incidental variants’’—those mutant alleles
that are unrelated to the conditions for which patients
undergo sequencing but that might have implications
for future health and reproductive decisions—should be
reported to patients and their families. This question
will become even more relevant as more and more
healthy individuals have their genomes sequenced.
Earlier this year, the American College of Medical
Genetics provided a list of genes for which they recom-
mend reporting high-confidence pathogenic alleles to
patients. Missing from this recommendation, however,
was a clear indication of the frequency with which
one might expect to find these alleles. In this paper,
Dorschner et al. addressed this question through
the study of 1,000 individuals who were included in the
National Heart, Lung, and Blood Institute Exome
Sequencing Project. Only 23 out of 1,000 individuals
were identified as having pathogenic or likely pathogenic
mutations in 114 genes in which mutations are linked to
disease. From this, the authors estimate a frequency ofy of Human Genetics. All rights reserved.
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3.4% for high-penetrance actionable alleles in adults of
European ancestry. The amount of time required for
literature review highlights the importance of developing
a centralized repository of disease alleles for use in clinical
practice.
Screening for Cilia Genes
Austin-Tse et al., page 672
There are several ways to go about finding a connection
between genes and diseases. In some cases, mutations
are identified in affected individuals, and then, through
statistical and functional testing, a connection can be
established. Other times, investigators will zero in on
particular genes that, on the basis of homology or
prior knowledge, might cause a particular phenotype
when mutated. As an example of the latter approach,
Austin-Tse et al. used information gained from work in
zebrafish and Chlamydomonas to generate a list of candi-
date genes whose mutations might lead to ciliary defects
in humans. This approach proved fruitful: from 295
individuals with primary ciliary dyskinesia, the authors
identified two families affected by CCDC65 mutations
and four families affected by mutations in C21orf59. Of
course, this leaves many unsolved cases, but given the
large number of genes already linked to cilia function or
formation, this is not entirely surprising. Although there
certainly are limitations to using this approach, the
ability to harness the power of model systems is a power-
ful tool in the study of human disease, especially for cases
in which exome sequencing might not be entirely
straightforward.588 The American Journal of Human Genetics 93, 587–588, OctoberUnraveling Common Variation in Transcriptional
Response to Glucocorticoids
Maranville et al., page 735
Glucocorticoid steroids are important for a wide variety of
functions, including metabolic and immune responses;
when bound to the glucocorticoid receptor, these mole-
cules exert their effects by bringing about transcriptional
changes. Individual sensitivity to glucocorticoids varies
and, because the effects are mediated through transcrip-
tional activation, could be a result of differences in the
regulation of the downstream genes. To better understand
this underlying variation, Maranville et al. identified tran-
scriptional changes in response to treatment at 27 genes
and discovered a glucocorticoid-responsive quantitative
trait locus, rs11129354, which was associated with
transcriptional changes at many of the same genes.
Allelic-imbalance assays demonstrated that the genotype
at rs11129354 significantly affected the expression of
the nearby gene, RBMS3, previously unidentified as a
player in glucocorticoid response, demonstrating that
rs11129354 can act as a cis-regulatory polymorphism.
Furthermore, RBMS3 appeared tomediate the transcription
at other genes in a genotype-dependent manner, suggest-
ing that rs1129354 can also act as a trans-regulatory poly-
morphism for many additional genes involved in steroid
response. Although previous studies have uncovered
glucocorticoid receptor alterations that almost eliminate
response, this study identified additional, genome-wide
variants associated with intermediate responses, providing
a reminder of the importance that common variation plays
in fine tuning many biological responses.3, 2013
